Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)

By Schilling G.   Bruweleit M.   Harbeck N.   Thomssen C.   Becker K.   Hoffmann R.   Villena C.   Schütte M.   Hossfeld D.   Bokemeyer C.   Wit M.  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 166-172

Springer Publishing Company

Access to resources Recommend Favorite

DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy

By  

Current Cancer Drug Targets, Vol. 10, Iss. 7, 2010-11 ,pp. : 758-771

Bentham Science Publishers

Access to resources Recommend Favorite

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

By Gullo Giuseppe   Bettio Daniela   Torri Valter   Masci Giovanna   Salvini Piermario   Santoro Armando  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite

Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers

By Desai Monica Dandona   Saroya Bikramajit Singh   Lockhart Albert Craig  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 3, 2013-03 ,pp. : 341-356

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab: A Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer

By Croom Katherine F.   Dhillon Sohita  

Drugs, Vol. 71, Iss. 16, 2011-11 ,pp. : 2213-2229

Adis International

Access to resources Recommend Favorite